cilostazol has been researched along with Carcinoma, Epidermoid in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We previously reported that human squamous cell carcinoma (SCC) cell lines refractory to cis-diaminedichloro-platinum II (cisplatin [CDDP]) had significant upregulation of the phosphodiesterase 3B gene (PDE3B), suggesting that inhibiting PDE3B suppresses CDDP resistance." | 1.39 | Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells. ( Baba, T; Iyoda, M; Kasamatsu, A; Ogawara, K; Saito, Y; Sakamoto, Y; Sakuma, K; Shiiba, M; Tanzawa, H; Usukura, K; Uzawa, K, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Uzawa, K | 1 |
| Kasamatsu, A | 1 |
| Baba, T | 1 |
| Usukura, K | 1 |
| Saito, Y | 1 |
| Sakuma, K | 1 |
| Iyoda, M | 1 |
| Sakamoto, Y | 1 |
| Ogawara, K | 1 |
| Shiiba, M | 1 |
| Tanzawa, H | 1 |
1 other study available for cilostazol and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Carcinoma, Squamous | 2013 |